{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:23:51Z","timestamp":1773422631724,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011633","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000}}],"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP120153"],"award-info":[{"award-number":["OPP120153"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K08 AI121422-01A1"],"award-info":[{"award-number":["K08 AI121422-01A1"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Moxidectin is a macrocyclic lactone registered for the treatment of human onchocerciasis. The drug has a good safety profile, large volume of distribution and a long elimination half-life. This paper reports tolerability data from the first use of moxidectin in persons with <jats:italic>Wuchereria bancrofti<\/jats:italic> infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In this randomized, open-label, masked-observer superiority trial, adults with <jats:italic>Wuchereria bancrofti<\/jats:italic> microfilaremia in C\u00f4te d\u2019Ivoire were randomized to 1 of 4 treatment arms: ivermectin + albendazole (IA), moxidectin + albendazole (MoxA), ivermectin + diethylcarbamazine (DEC) + albendazole (IDA), or moxidectin + DEC + albendazole (MoxDA). As part of a larger efficacy trial, all participants were closely monitored for 7 days after treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>One hundred sixty-four individuals were treated, and monitored for treatment emergent adverse events (TEAE). Eighty-seven participants (53%) experienced one or more mild (grade 1) or moderate (grade 2) TEAE. Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA). There were no serious adverse events. There were no significant differences in frequency or types of TEAE between treatment groups (IA = 22\/41 (53%), MoxA = 24\/40 (60%), IDA = 18\/41 (44%), MoxDA = 15\/42 (36%), p = 0.530). Fifty-nine participants (36%) had multiple TEAE, and 8.5% had a one or more grade 2 (moderate) TEAE. Grade 2 TEAE were more frequent after triple drug treatments (IDA, 14.6%; MoxDA, 9.5%) than after two-drug treatments (IA, 7.3%; MoxA, 2.5%). There was no difference in TEAEs based on baseline Mf counts (OR 0.69 (0.33, 1.43), p-value 0.319).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>All treatment regimens were well tolerated. We observed no difference in safety parameters between regimens that contained ivermectin or moxidectin.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Clinicaltrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04410406\" xlink:type=\"simple\">NCT04410406<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0011633","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T17:29:07Z","timestamp":1695058147000},"page":"e0011633","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in C\u00f4te d\u2019Ivoire: A randomized controlled superiority study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-1866","authenticated-orcid":true,"given":"Catherine M.","family":"Bjerum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin G.","family":"Koudou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allassane F.","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles W.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal T.","family":"Gabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Budge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"pntd.0011633.ref001","first-page":"497","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2020 \u2013Programme mondial pour l\u2019\u00e9limination de la filariose lymphatique: rapport de situation, 2020","volume":"96","author":"World Health Organization = Organisation mondiale de la S","year":"2021","journal-title":"Weekly Epidemiological Record = Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire"},{"issue":"3","key":"pntd.0011633.ref002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"7","key":"pntd.0011633.ref003","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Cote d\u2019Ivoire: An Open-label Randomized Controlled Trial.","volume":"71","author":"CM Bjerum","year":"2020","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"2","key":"pntd.0011633.ref004","doi-asserted-by":"crossref","first-page":"e0010096","DOI":"10.1371\/journal.pntd.0010096","article-title":"Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial","volume":"16","author":"L Tavul","year":"2022","journal-title":"PLoS neglected tropical diseases"},{"issue":"6","key":"pntd.0011633.ref005","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study","volume":"16","author":"GJ Weil","year":"2019","journal-title":"PLoS Med"},{"key":"pntd.0011633.ref006","author":"WHO","year":"2017"},{"issue":"10154","key":"pntd.0011633.ref007","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"NO Opoku","year":"2018","journal-title":"Lancet"},{"key":"pntd.0011633.ref008","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1017\/S0031182000007423","article-title":"An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis","volume":"121","author":"J Horton","year":"2000","journal-title":"Parasitology"},{"issue":"1","key":"pntd.0011633.ref009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4269\/ajtmh.1991.44.3","article-title":"Comparison of high dose ivermectin and diethylcarbamazine for activity against bancroftian filariasis in Haiti","volume":"44","author":"FO Richards","year":"1991","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"pntd.0011633.ref010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/0035-9203(91)90375-9","article-title":"A placebo-controlled double-blind trial for the treatment of bancroftian filariasis with ivermectin or diethylcarbamazine","volume":"85","author":"M Sabry","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"pntd.0011633.ref011","doi-asserted-by":"crossref","first-page":"e0007325","DOI":"10.1371\/journal.pntd.0007325","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Cote d\u2019Ivoire","volume":"13","author":"C Edi","year":"2019","journal-title":"PLoS neglected tropical diseases"},{"issue":"5","key":"pntd.0011633.ref012","doi-asserted-by":"crossref","first-page":"e0006454","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"PJ Budge","year":"2018","journal-title":"PLoS neglected tropical diseases"},{"issue":"10","key":"pntd.0011633.ref013","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/0091270003257456","article-title":"The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans","volume":"43","author":"MM Cotreau","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"pntd.0011633.ref014","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cts.12583","article-title":"Evaluation of the Cardiac Safety of Long-Acting Endectocide Moxidectin in a Randomized Concentration-QT Study","volume":"11","author":"SA Kinrade","year":"2018","journal-title":"Clinical and translational science"},{"issue":"1","key":"pntd.0011633.ref015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4269\/ajtmh.2012.11-0415","article-title":"The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial","volume":"86","author":"JM Korth-Bradley","year":"2012","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"pntd.0011633.ref016","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1128\/AAC.00311-11","article-title":"Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women","volume":"55","author":"JM Korth-Bradley","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0011633.ref017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2160763X11432508","article-title":"Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin","volume":"1","author":"JM Korth-Bradley","year":"2012","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"pntd.0011633.ref018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cpdd.81","article-title":"Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects","volume":"3","author":"JM Korth-Bradley","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1)","key":"pntd.0011633.ref019","first-page":"CD003753","article-title":"Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis","volume":"1","author":"CL Macfarlane","year":"2019","journal-title":"The Cochrane database of systematic reviews"},{"issue":"3","key":"pntd.0011633.ref020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1473-3099(22)00589-8","article-title":"Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"23","author":"S Welsche","year":"2023","journal-title":"Lancet Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011633","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:50:23Z","timestamp":1695923423000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011633"}},"subtitle":[],"editor":[{"given":"Gregory","family":"Deye","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011633","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011633","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}